

| File S3. Adjuvant chemotherapy of the matched patients | | | |
|--|------------------------------------|--|---|
| Pair no./sex/ age (year)/ Tx. | Primary cancer type | Adjuvant chemotherapy agent and cycles (#N) | Period |
| 1 / F / 27 / TES | RCC | VAC/IE #5 Cytosan/Topotecan #4 | -2001.11 2004.7-2004.10 |
| 1 / M / 84 / SABR | RCC | Pazopanib | 2019.2-2021.3 |
| 2 / M / 77 / TES | RCC | None | |
| 2 / M / 80 / SABR | RCC | None | |
| 3 / M / 61 / TES | Thyroid cancer | RAI #12 | -2010.8 |
| 3 / F / 62 /7A SABR | Thyroid cancer | RAI #7 | 2007.6-2016.8 |
| 4 / M / 64 / TES | Poorly differentiated carcinoma | None | |
| 4 / M / 66 / SABR | HCC | Sorafenib Regorafenib Nivolumab | 2018.12-2019.1 2019.1-2019.4 2019.5-2019.7 |
| 5 / M / 56 / TES | HCC | Sorafenib | 2012.1-2012.3 |
| 5 / F / 67 / SABR | HCC | Sorafenib Regorafenib PD1 + LAG3 #10 5-fluorouracil/Cis-platinum #5 Adriamycin #1 | 2017.7-2018.7 2018.10-2019.5 2019.9-2020.4 2020.4-2020.9 2020.9-11 |
| 6 / M / 71 / TES | Thyroid cancer | RAI #5 | -2013.11 |
| 6 / F / 58 / SABR | Breast cancer | Zoladex/Tamoxifen Letrozole Aromasin #24 Faslodex #21 Capecitabine #39 Paclitaxel #6 Gemcitabine/Cisplatin #13 | 2012.7 2012.7-2014.12 2014.12-2017.4 2017.5-2017.10 2019.1-2021.7 2021.8-2022.3 2022.3- |
| 7 / M / 69 / TES | HCC | Nexavar #6 | -2012.6 |
| 7 / M / 55 / SABR | HCC | Sorafenib Nivolumab | 2019.5-2019.12 2020.2-2021.2 |
| 8 / F / 48 / TES | Breast cancer | Tamoxifen #10 Docetaxel #28 | -2016.3 -2018.9 |
| 8 / F / 50 / SABR | Breast cancer | Tamoxifen Letrozole Xeloda #69 | 2014.9-2018.4 2018.7-2018.12 2018.12- |
| 9 / M / 61 / TES | RCC | Sunitinib #5 Everolimus #11 | 2013.2-2013.9 2013.10-2014.8 |
| 9 / M / 64 / SABR | RCC | Bevacizumab Sunitinib Everolimus | 2015.8-2017.3 2017.4-2017.5 2017.5-2017.6 |
| 10 / M / 66 / | RCC | Sunitinib #20 | 2011.1-2013.3 |

| | | | |
|---------------|---------------------------------|--------------------------------|-----------------|
| TES | | RAD001 #3 | 2013.6-2013.8 |
| 10 / M / 69 / | RCC | Sorafenib #3 | 2013.9-2013.12 |
| SABR | | Pazopanib | 2017.1-2019.2 |
| | | Axitinib | 2019.2-2019.12 |
| | | Cabozantinib | 2019.12-2020.5 |
| | | Everolimus | 2020.5-2021.6 |
| 11 / M / 52 / | HCC | FOLFOX #2 | 2013.11-2013.12 |
| TES | | Paclitaxel/Cisplatin #8 | 2014.1-2014.6 |
| | | FOLFIRI #6 | 2014.7-2014.10 |
| 11 / M / 56 / | HCC | Sorafenib | 2019.1-2019.3 |
| SABR | | Regorafenib | 2019.3-2019.6 |
| | | Nivolumab | 2019.6-2019.9 |
| 12 / F / 54 / | Breast cancer | Adriamycin/Cyclophosphamide #4 | |
| TES | | Paclitaxel #4 | -2014.4 |
| | | Xeloda #8 | -2019.6 |
| | | Verzenio/Faslodex #25-27 | 2020.7- |
| 12 / F / 53 / | Breast cancer | Docetaxel #8 | 2017.6-2017.11 |
| SABR | | | |
| 13 / M / 56 / | Thyroid cancer | RAI #1 | 2016.1 |
| TES | | | |
| 13 / M / 62 / | Thyroid cancer | RAI #1 | 2015.1 |
| SABR | | Sorafenib | 2015.2-2016.3 |
| | | Lenvatinib | 2016.7-2019.10 |
| | | Adriamycin/Cisplatin | 2019.12-2020.2 |
| 14 / M / 38 / | RCC | Sunitinib #16 | -2017.12 |
| TES | | Atezolizumab/Cobimetinib | 2017.12-2018.7 |
| | | Axitinib | 2018.7-2019.4 |
| | | Cabozantinib | 2019.5-2019.7 |
| 14 / M / 78 / | RCC | Pazopanib | 2019.3-2021.12 |
| SABR | | | |
| 15 / M / 32 / | Adrenal cortical carcinoma | Mitotane | 2014.1-2014.7 |
| TES | | Doxorubicin/Cisplatin #6 | 2014.10-2015.1 |
| 15 / M / 59 / | HCC | Regorafenib | 2018.11-2019.1 |
| SABR | | Cabozantinib | 2019.12-2020.3 |
| 16 / M / 51 / | RCC | Sunitinib | 2014.3-2017.3 |
| TES | | Everolimus | 2017.3-2019.5 |
| | | Cabozantinib | 2021.12-2022.1 |
| | | Nivolumab #2 | 2022.1-2022.2 |
| 16 / M / 55 / | RCC | Pazopanib | 2018.12-2018.1 |
| SABR | | Sunitinib | 2019.2-2020.11 |
| | | Axitinib | 2020.12-2021.9 |
| | | Cabozantinib | 2021.9- |
| 17 / M / 53 / | Thyroid cancer | RAI #2 | 2020.4-2021.1 |
| TES | | | |
| 17 / F / 50 / | Breast cancer | TCHP/Neulapeg #6 | 2016.6-9 |
| SABR | | Herceptin #8 | 2016.11-2017.4 |
| | | TDM-1 #15 | 2017.7-2018.7 |
| | | Eribulin/Trastuzumab #24 | 2018.9-2020.1 |
| | | Trastuzumab Deruxtecan #42 | 2020.3- |
| 18 / M / 33 / | Poorly differentiated carcinoma | Docetaxel/Cyclophosphamide #4 | 2015.8-2015.10 |
| TES | | | |
| 18 / M / 47 / | HCC | Sorafenib | 2017.5-2018.9 |
| SABR | | | |

| | | | |
|-----------------------|-------|---------------------------|----------------|
| 19 / M / 53 / TES | NSCLC | Cisplatin/Vinorelbine #4 | 2011.11-2012.1 |
| | | Gefitinib | 2012.9-2013.3 |
| | | Cisplatin/Gemcitabine #2 | 2013.5-2013.6 |
| | | Paclitaxel/Carboplatin #2 | 2013.6-2013.8 |
| | | Pemetrexed #2 | 2013.8-2013.9 |
| 19 / M / 60 / SABR | NSCLC | LXH254#2 | 2019.1-2 |